-

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) held on May 21, 2025. Detailed results of the vote follow:

Name

For

 

Against

 

Broker Non-Votes

Nathalie Bernier

 

337,617,248

 

1,924,336

 

8,383,437

Gary Hu

 

337,591,706

 

1,949,878

 

8,383,437

Brett Icahn

 

337,474,287

 

2,067,297

 

8,383,437

Sarah B. Kavanagh

 

337,602,211

 

1,939,373

 

8,383,437

Karen L. Ling

 

337,526,114

 

2,015,470

 

8,383,437

John A. Paulson

 

337,650,735

 

1,890,849

 

8,383,437

Russel C. Robertson

 

337,600,880

 

1,940,704

 

8,383,437

Thomas W. Ross, Sr.

 

337,583,018

 

1,958,566

 

8,383,437

Brenton L. Saunders

 

337,592,062

 

1,949,522

 

8,383,437

Andrew C. von Eschenbach, M.D.

 

337,607,276

 

1,934,308

 

8,383,437

Shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, appointment of PricewaterhouseCoopers LLP to serve as auditor until the close of the Company's 2026 Annual Meeting of Shareholders, and authorization for the board of directors to fix the auditor’s remuneration.

The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

More News From Bausch + Lomb Corporation

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company’s broad portfolio of products...

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. “We’re doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward,” said Brent Saunders, chairman and CEO, Bausch + Lomb. Select Company Highlig...

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2 Drawing on more than two decades of scientific research, the publication synt...
Back to Newsroom